Abstract:
Type 1 diabetes is a progressive autoimmune disease characterized by the immune system attacking and destroying insulin producing beta cells in the pancreas. The progression occurs in 3 stages. Stage 1 and 2 are the pre-symptomatic stages and can be identified by the presence of ilet antibodies. Early stages 1 and 2 can occur months to years before the onset of symptoms and progression to stage 3 (clinical) type 1 diabetes. Selecting high risk individuals and diagnosing early autoimmune diabetes allows for monitoring of hyperglycemia and need for insulin, prevention of ketoacidosis (DKA) and subsequent complications, as well as potentially delaying progression to stage 3 through emerging immunotherapies.
Biography:
Lauri Deane is a Board-Certified Advanced Practice Registered Nurse (APRN, FNP-C), Certified Diabetes Care and Education Specialist (CDCES) and is Board Certified in Advanced Diabetes Management (BC-ADM). With 14+ years' experience in nursing, she has spent the last 8 years focusing on advancements in diabetes management and treatments. Lauri is an expert in the use of diabetes technologies such as insulin pumps and continuous glucose monitors. Lauri is a professional member of the American Diabetes Association (ADA) and actively participates in interest groups regarding autoimmune diabetes. Previous experience includes academic medicine with the University of Miami Diabetes Research Institute. Lauri is an advocate for her patients and families living with type 1 diabetes and is passionate about educating health care providers on early detection. Lauri’s dedication to this specialization is rivaled only by her commitment to patient education, empowerment and support.
